Sentinus LLC’s Novartis NVS Stock Holding History

Sentinus LLC’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,894	Closed	-$218K	–	191
2024 Q3	$218K	Buy	+1,894	New	+$215K	0.07%	172

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Sentinus LLC's NVS Position: Q4 2024 in Review

Sentinus LLC sold out of Novartis (NVS) in Q4 2024, closing a stake of 1,894 shares — an estimated $218K sold.

Sentinus LLC first reported a position in NVS in Q3 2024 and held it in 1 quarter. The position peaked at $218K in Q3 2024. 1,340 funds tracked by Wall St. Rank hold NVS as of Q4 2024.

Sentinus LLC reported no remaining Novartis position as of Q4 2024 after selling out during the quarter.
Sentinus LLC sold 1,894 Novartis shares in Q4 2024, an estimated $218K.
Sentinus LLC first reported a position in Novartis in Q3 2024 and held it in 1 quarter.
Sentinus LLC's Novartis position peaked at $218K in Q3 2024.
1,340 funds tracked by Wall St. Rank held Novartis as of Q4 2024.

Based on Sentinus LLC's 13F filing for Q4 2024, filed 14 Feb 2025.